Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Solid Biosciences Inc. (NASDAQ:SLDB) have received an average rating of “Moderate Buy” from the twelve analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $17.00.

Several brokerages have recently commented on SLDB. Guggenheim began coverage on Solid Biosciences in a research report on Friday, March 20th. They issued a “buy” rating and a $26.00 price objective on the stock. HC Wainwright boosted their price objective on Solid Biosciences from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Solid Biosciences in a research report on Friday, March 20th. Wedbush lowered their price objective on Solid Biosciences from $17.00 to $16.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Finally, Piper Sandler restated an “overweight” rating and issued a $18.00 price objective (up from $17.00) on shares of Solid Biosciences in a research report on Wednesday, May 13th.

More Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Solid Biosciences and maintained a $25 price objective, signaling continued long-term upside confidence in Read More..
• Neutral Sentiment: The analyst raised its FY2030 EPS estimate to $1.88 from $1.81, implying longer-dated profitability may still improve. Article Title
• Negative Sentiment: HC Wainwright cut earnings estimates across several near- and medium-term periods, including FY2026 to -$1.72 from -$1.43, FY2027 to -$1.72 from -$1.36, and FY2028 to -$1.33 from -$0.60, which may be weighing on the stock. Article Title
• Negative Sentiment: Shorter-term forecasts were also reduced, with Q2 2026 through Q4 2027 EPS now expected in the -$0.41 to -$0.44 range, suggesting continued losses over the next several quarters. Article Title

Solid Biosciences Stock Down 7.5%

Shares of Solid Biosciences stock opened at $6.70 on Friday. The stock’s 50-day simple moving average is $7.41 and its 200-day simple moving average is $6.51. Solid Biosciences has a 52 week low of $3.79 and a 52 week high of $8.87. The company has a market capitalization of $659.62 million, a price-to-earnings ratio of -3.44 and a beta of 2.43.

Solid Biosciences (NASDAQ:SLDB) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.12). On average, equities analysts expect that Solid Biosciences will post -1.9 earnings per share for the current year.

Institutional Investors Weigh In On Solid Biosciences

A number of hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC lifted its position in shares of Solid Biosciences by 0.6% in the first quarter. Perceptive Advisors LLC now owns 11,906,646 shares of the company’s stock worth $85,728,000 after buying an additional 73,107 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Solid Biosciences by 12.3% in the first quarter. Bank of America Corp DE now owns 386,793 shares of the company’s stock worth $2,785,000 after buying an additional 42,499 shares in the last quarter. Stempoint Capital LP purchased a new stake in shares of Solid Biosciences in the first quarter worth about $1,407,000. Janus Henderson Group PLC purchased a new stake in shares of Solid Biosciences in the first quarter worth about $28,877,000. Finally, Ally Bridge Group NY LLC lifted its position in shares of Solid Biosciences by 85.4% in the first quarter. Ally Bridge Group NY LLC now owns 766,974 shares of the company’s stock worth $5,522,000 after buying an additional 353,349 shares in the last quarter. 81.46% of the stock is currently owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.